the bar chart illustrates the gross sales’s proportion of a drug company in three regions: America, Europe, Asia, from 2000 to 2006.
Overall, there is an approximate balance in total sales throughout the period. However, Asia is the only region with an increasing sales at the end of the phase. Whereas both America and Europe saw fluctuation in their expenditures.
On one hand, the drug company’s Asian sales resgistered a remarkable rise in total sales. From 25 units in 2002 to 40 units in 2006. On the contrast, America witnessed a significant decline in the period, from 41 units to 30 units, respectively. Whereas the European market had significant changing in gross sales during 5 years.
As can be seen, the America’s total sales started off with 41 units, then decreased dramatically to 27 units in 2004, then slightly increased to 30 units in 2006. On the contrast, Europe total sales began with a rising trend, escalated from 24 units in 2002 to 38 units in 2004, then fell off again back to 30 units in 2006. It is visible that the American market dominated the drug company total sales in 2002, but then the gross sales was nearly equally divided between the three factors, with Asia as the leading market taking 40 percents.